Skip to content

Home Sleep Testing in Neuromuscular Disease Patients

Home Sleep Testing in Neuromuscular Disease Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00695591
Acronym
HSTNMD
Enrollment
9
Registered
2008-06-12
Start date
2008-07-31
Completion date
2009-07-31
Last updated
2014-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuromuscular Disease

Keywords

Home sleep testing neuromuscular disease, Neuromuscular disease patients with FEV1<50% of predicted

Brief summary

Lay Summary Patients with severe neuromuscular develop hypoventilation, which leads to elevated carbon dioxide levels. Measuring only oxygen saturation levels with pulse oximetry may be inadequate. End tidal carbon dioxide levels or arterial blood gases should be measured periodically, depending on the clinical condition of the patient. A thorough review of systems will help define any problems. Patients who are hypoventilating often have elevated carbon dioxide levels at night and complain of a morning headache, restlessness or nightmares, and poor quality sleep. This may cause daytime sleepiness. Insufficient respiration with hypoxia may occur later, especially if the lung is damaged by chronic aspiration. We propose to evaluate the use of the Nonin LifeSense monitor in home evaluation of respiration, oxygen level, heart rate, and carbon dioxide level and to develop interpretation of the results that will lead to appropriate interventions for apnea, and insufficient respiration. Relevance to MDA Fewer than one per cent of the Muscular Dystrophy Association have pulmonologists as co-directors.Late referral of progressive restrictive lung disease leads to invasive support of respiratory failure. Early initiation of non invasive ventilation techniques requires patience on the part of the caregiver and exploration of mask interfaces and ventilation techniques. In addition, the development of new therapies, currently manifested through enhanced diagnostic accuracy, will require new signal for initiation and in the assessment of success or failure. Aims Aim 1. To assess the utility of a small portable device (LifeSense Monitor Nonin Medical Inc. Plymouth Minnesota) with extended recording capabilty to provide accurate diagnosis of hypoventilation. Aim 2. To provide an easily interpretable report defining sleep hypoxemia, hypercapnea, and apnea. Aim 3. To promote early evaluation and treatment of the respiratory problems in centers that do not have pumonologists as these are essential to prognosis, whether of survival or of quality of life, in neuromuscular diseases.

Interventions

OTHEREvaluation for Nocturnal non invasive ventilation

Patients will be referred for evaluation for NNIV is indicated in patients with diurnal Pa,CO2 \>6.0 Pa; and 2) nocturnal Sa,O2 \<88% for 5 consecutive min. End tidal CO2 representing equivalent values will be referred for NNIV

Sponsors

Landon Pediatric Foundation
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
8 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of neuromuscular disease * Must have home caregivers

Exclusion criteria

* No home caregiver

Design outcomes

Primary

MeasureTime frame
1. End tidal CO2 catheter is tolerated for six hours or more3 months

Secondary

MeasureTime frame
1. Interpretable data are captured for oximetry, heart rate, and end-tidal CO23 months
2. An interpretive report is generated that will guide the non-pulmonary physician in potential interventions6 months
2. Patients and parents are able to apply the monitors at home and a six hour data set is collected3 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026